Kala Pharmaceuticals announced the appointment of Francis Mah, M.D., as Chief Medical Advisor. In this newly established role, Dr. Mah will provide support for Kala‘s clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in this role on a part time basis while continuing his ongoing position as Director of Cornea and External Disease and the Co-Director, Refractive Surgery at Scripps Clinic.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KALA:
- Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
- Kala announces safety update from Cohort 1 of CHASE Phase 2b trial
- Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
- Kala Pharmaceuticals price target raised to $20 from $12 at H.C. Wainwright
- Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
